Navigation Links
Pinnaclife Animal Health to attend CVC Conference in San Diego
Date:12/4/2012

olecules that has proven to improve wound-healing rates by 50% as compared to control.  The blend is based upon a combination of biologically active polyphenol fractions, from the olive, combined with four amino acids and their co-factors.  The amino acids are L-proline, L-taurine, N-acetyl-L-cysteine and glycine.  Each ingredient is scientifically balanced individually and in combination ratios that ensure optimal healing rates.  Baker IDI Laboratories in Melbourne, Australia preformed the research.  Olivamine10™ has been used for over a decade in North America's number one selling hospital-based skin and wound healing products line.  To view studies visit the following link: Wound Healing Results.

The products are distributed exclusively through NDC, Inc. Products are currently available with First Veterinary Supply and Midwest Veterinary Supply.

FOR MORE INFORMATION:
CONTACT:
Ben Langston, Territory Manager
Pinnaclife Animal Health
P: 319-351-3201
blangston@pinnaclife.com


'/>"/>
SOURCE Pinnaclife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
2. Pinnaclife To Sponsor The Nebraska Academy of Nutrition and Dietetics Fuel Up With Color 5K And 1 Mile Fun Run
3. Pinnaclife Sponsors "The Prevent Event: Breast Cancer Education And You!"
4. Pinnaclife Animal Health Features Seal N Heal Wound Shield in New Veterinary Dermatologist Tested and Approved Product Line!
5. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
6. Animal Biotechnology - Technologies, Markets and Companies
7. Animal Husbandry Equipment Market in United States: Business Report 2011
8. Novel compound halts tumor spread, improves brain cancer treatment in animal studies
9. The Italian Institute of Prophylaxis against Animal Diseases (IZS) to test effectiveness of BeesFree Inc.s Technology in Combating Colony Collapse Disorder
10. NextGen introduces its first generation of animal biomarker products for development of brain disorder diagnostics
11. Advanced Animal Diagnostics Adds Sales & Marketing Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...
(Date:5/21/2013)... 21, 2013 Smarter Security, Inc., provider ... today announced that Genzyme, a Sanofi company and leading ... Detective® CL for a multi-use facility in the United ... other Genzyme buildings, this latest order underscores the satisfaction ... tailgate detection device improving doorway access control. ...
(Date:5/21/2013)... ALBANY, New York , May 21, 2013 /PRNewswire/ ... published by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip ... Science Research, IVD Tests) - U.S. Industry Analysis, Size, Share, ... USD 2.4 billion in 2011 and is expected to ... 2018, to reach an estimated value of USD 4.7 ...
(Date:5/21/2013)... May 21, 2013 As the ... strong push within the industry to deliver better ... Organizations and pharma companies often means turning big ... Microtablets, developed in collaboration with Sensidose AB and ... can bring products to market sooner. The partnership ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... review, the Company is initiating a U.S.,Phase ... REOLYSIN(R) in,combination with paclitaxel and carboplatin in ... K-RAS or EGFR-activated tumours. The Principal,Investigator is ...
... /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, Inc. (NASDAQ: OGXI ... that it has granted to Eagle Pharmaceuticals, ... commercialize TOCOSOL(R),Paclitaxel. Under the terms of the ... from future TOCOSOL Paclitaxel sales and a,percentage ...
... Germany, Sept. 1 ,Boston Scientific Corporation (NYSE: ... its landmark SYNTAX trial comparing percutaneous coronary ... Stent,System to contemporary coronary artery bypass graft ... significant differences,between PCI and CABG in rates ...
Cached Biology Technology:/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 2/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 3/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 4OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 2OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 3Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 2Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 3Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 4Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 5
(Date:5/21/2013)... 21, 2013 Royal Philips Electronics (NYSE: PHG, ... first portable ultrasound with Philips, industry leading Live 3D ... CX50 xMATRIX with available Live 3D TEE and ICE ... at the EuroPCR, official meeting for the European Association ... Since its launch in 2012, Philips CX50 xMATRIX has ...
(Date:5/21/2013)... the way genes function without changing the underlying ... blood of pregnant women during any trimester, potentially ... the weeks after giving birth, and an opportunity ... findings of the small study involving 52 pregnant ... Molecular Psychiatry . , "Postpartum depression can be ...
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... "Basic science and clinical medicine move at different pace ... strategies to manage cancer patients. We need to efficiently translate ... in the clinic." Sherene Loi and Fabrice Andr, ... four major areas: , Molecular pathology, the roots ...
... award-winning research project, funded by the British Heart Foundation (BHF), ... how doctors predict a patient,s risk of having a heart ... a BHF Centre of Research Excellence, in collaboration with the ... of combining PET and CT scanning to image the disease ...
... Mass. A team of kinesiology researchers led by ... recently received a 2.5-year, $975,000 grant through the Navy ... study how the average 100-lb. equipment load carried by ... affects their survivability, likelihood of injury and ability to ...
Cached Biology News:Fourth IMPAKT Breast Cancer Conference 2Fourth IMPAKT Breast Cancer Conference 3Scientists develop new technique that could improve heart attack prediction 2Kinesiology team gets $975,000 Defense grant to study effects of heavy loads on soldiers 2
... coating using advanced automated high throughput microplate processing equipment that ... also accommodate virtually any lot size of the following formats ... 8 and 12 well strips, ... 384 well microplate, ...
...
... Mynox is the first biological ... killing them, and not just ... the only anti-mycoplasma agent that ... virus stocks directly. The cytotoxicity ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: